ClinicalTrials.gg
Active, not recruitingNCT07396467IPF-LC-IOUpdated Mar 17, 2026

Clinical Outcomes and Immunotherapy in Lung Cancer With Pulmonary Fibrosis

An observational study in Lung Cancer (Diagnosis), Pulmonary Fibrosis and Interstitial Lung Diseases, sponsored by The First Affiliated Hospital with Nanjing Medical University. Active, not recruiting at 1 site in China. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-03-17.

Sponsored by The First Affiliated Hospital with Nanjing Medical University · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
200
Ages
18 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 850 studies in Lung Neoplasms with a site in China — 376 open to participants now, 423 under way, 34 of them phase 3. Lung Neoplasms · China.

Planned enrollment
153rd of 259
200 · median 307
Started
2025
with 107 others
Observational
259 of 850
114 open now
Primary completion
2026-12
later than 187 of 422 live
Registered
757th of 850
by date

Among the 850 studies in Lung Neoplasms with a site in China, this one is the 153rd largest by planned enrollment of the 259 observational ones that give a count, is one of 108 that started in 2025, is one of 259 observational ones, reaches primary completion later than 187 of the 422 other live ones, and was the 757th registered.

Lung Neoplasms

5,436 studies on the registry are indexed under Lung Neoplasms; 1,350 are open to participants now.

Browse Lung Neoplasms studies →

Open to participants now

376 of the 850 studies in Lung Neoplasms with a site in China are open now. Recruiting first, the newest first:

371 more — sign in →

All 376 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 997 Lung Neoplasms studies recruiting now, 686 (69%) set no upper age limit and 143 (14%) stop at 75 or younger; 45 take children under 18; 143 take healthy volunteers.

This study: 18 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 850 studies in Lung Neoplasms with a site in China, or all of them as a file.
02

Study summary

This retrospective observational study evaluates immune checkpoint inhibitor (ICI)-related outcomes in lung cancer patients with concomitant pulmonary fibrosis/interstitial lung disease (ILD) and determines how fibrosis/ILD modifies immunotherapy effectiveness and safety. The study characterizes the clinical, radiographic, pathological, and molecular features of lung cancer with ILD and examines their associations with ICI response and survival. A comparator cohort of lung cancer patients without radiographic ILD from the same institution and time period is included to compare ICI effectiveness (e.g., response and survival outcomes) and pulmonary toxicity signals, including pneumonitis and acute ILD exacerbation.

In a translational sub-study, archived lung tumor specimens undergo single-cell and spatial transcriptomic profiling to identify fibrosis-associated tumor-microenvironment programs that may underlie differential immunotherapy outcomes.

Read the detailed description

Lung cancer with concomitant pulmonary fibrosis/interstitial lung disease (ILD) represents a clinically challenging population in which immune checkpoint inhibitor (ICI) treatment may be influenced by baseline lung vulnerability and a distinct tumor immune microenvironment. This single-center retrospective observational cohort study evaluates how fibrosis/ILD status and related clinical features are associated with immunotherapy use, effectiveness, and safety.

Patients with pathologically confirmed lung cancer and radiographic evidence of pulmonary fibrosis/ILD diagnosed and treated at Jiangsu Province Hospital (The First Affiliated Hospital of Nanjing Medical University) are identified. A comparator cohort of lung cancer patients without radiographic ILD from the same institution and time period is assembled to enable direct comparisons of immunotherapy outcomes. Baseline demographics, smoking history, comorbidities, pulmonary function and imaging features (when available), tumor histology and stage, relevant laboratory indices, and molecular testing results are collected and analyzed. Associations between these variables and ICI exposure or clinical outcomes are evaluated.

Primary analyses focus on immunotherapy-related endpoints, including real-world measures of ICI effectiveness such as objective response and survival outcomes captured in routine clinical care. Safety analyses include ILD-relevant outcomes such as immune-related pneumonitis, acute exacerbation of underlying ILD, treatment interruption or discontinuation, and other clinically significant pulmonary adverse events. Comparative analyses evaluate whether patients with lung cancer and fibrosis/ILD experience different ICI effectiveness or higher pulmonary toxicity risk compared with patients without ILD. Additional analyses explore which clinical, radiographic, pathological, or molecular features within the ILD cohort are associated with favorable or unfavorable immunotherapy outcomes.

To investigate potential mechanisms underlying differential immunotherapy responses in fibrosis-associated lung cancer, a translational sub-study analyzes available archived lung tumor specimens (e.g., bronchoscopic biopsy, computed tomography-guided biopsy, or surgical samples). Single-cell transcriptomics and spatial transcriptomics are performed to compare tumors arising in a fibrotic lung environment with tumors from patients without ILD. These analyses identify fibrosis-associated cellular states, immune microenvironment composition, and signaling programs that may contribute to altered immunotherapy sensitivity or toxicity. Findings from the multi-omics analyses are integrated with clinical outcome data to generate mechanistic hypotheses and potential biomarkers relevant to immunotherapy decision-making in lung cancer patients with pulmonary fibrosis/ILD.

03

Conditions studied

  • Lung Cancer (Diagnosis)
  • Pulmonary Fibrosis
  • Interstitial Lung Diseases

Keywords

  • Lung cancer
  • Pulmonary fibrosis
  • Immune checkpoint inhibitor
  • Tumor microenvironment
  • Single-cell RNA sequencing
  • Interstitial lung disease
04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Retrospective, single-center observational cohort study of patients with pathologically confirmed lung cancer and imaging-confirmed interstitial lung disease (ILD) diagnosed at Jiangsu Provincial People's Hospital between January 2019 and September 2025. Eligible cases will be identified from hospital information systems and clinical records. Clinical characteristics, laboratory results, imaging, pathology and molecular reports will be extracted from Hospital Information System (HIS), Laboratory Information System (LIS), and Picture Archiving and Communication System (PACS) databases. Available tumor tissue specimens (bronchoscopic biopsy, CT-guided lung biopsy, or surgically resected lung tissue) will be collected for spatial transcriptomics analysis. Patients whose tumor location does not overlap with ILD-involved areas will be excluded.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed lung cancer.

Interstitial lung disease identified on chest imaging (e.g., high-resolution computed tomography).

Diagnosed and treated at Jiangsu Provincial People's Hospital between January 2019 and September 2025.

Exclusion criteria

Exclusion Criteria:

  • The anatomical location of the lung cancer lesion does not overlap with the ILD-involved area.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
200 participants (estimated)
Patient registry
No

Groups and cohorts

  • Lung cancer without pulmonary fibrosis

    patients with lung cancer without lung fibrosis

    Other: there is no intervention

  • Lung cancer with pulmonary fibrosis

    Other: there is no intervention

Interventions

  • Otherthere is no intervention

    there is no intervention

06

What researchers measure

Primary outcomes

  1. Overall survival (OS)

    Time frame: up to 36 months

Secondary outcomes

  1. Progression-free survival (PFS)

    Time frame: up to 36 months

  2. Objective response rate (ORR)

    Time frame: up to 36 months

Other outcomes

  1. Adverse events (AEs)

    adverse event

    Time frame: up to 36 months

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2025 (actual). Primary completion is estimated for Dec 2026, 13 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 1, 2026
First posted
Feb 9, 2026
StartActual
Nov 1, 2025
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2028
Last update
Mar 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07396467
Responsible party
Sponsor
First posted
Feb 9, 2026
Start date
Nov 1, 2025
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Mar 17, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion